0000000000600002

AUTHOR

Alessandra Battaglia

showing 2 related works from this author

Baseline absolute neutrophil count (ANC), derived neutrophil-to-lymphocyte ratio (dNLR) and platelet-to-lymphocyte ratio (PLR) and outcome in non sma…

2017

Nivolumab (N) is a novel therapeutic option in NSCLC, with a significant survival gain compared with Docetaxel (D). However, predictive biomarkers are lacking and no strategies have been adopted to date for optimal patients (pts) selection. The presence of systemic inflammation has been correlated with poor outcome in many cancer types. We aimed to evaluate whether there is a correlation between some indicators of inflammation and response in pts treated with N or D.

Oncologymedicine.medical_specialtybusiness.industryLymphocytenon-small cell lung cancer (NSCLC)Hematology030204 cardiovascular system & hematologyNSCLCmedicine.diseasePreliminary analysis03 medical and health sciences0302 clinical medicinemedicine.anatomical_structureOncologyDocetaxel030220 oncology & carcinogenesisInternal medicinemedicineAbsolute neutrophil countPlateletNeutrophil to lymphocyte ratioNivolumabbusinessmedicine.drugAnnals of Oncology
researchProduct

Retrospective analysis of the therapeutic efficacy of platinum/etoposide schedules in the treatment of advanced poor differentiated neuroendocrine ca…

2017

Oncologymedicine.medical_specialtyLungSettore MED/06 - Oncologia Medicabusiness.industryHematologycarcinomas of the lungNeuroendocrine Carcinomasmedicine.anatomical_structureOncologyInternal medicinemedicineRetrospective analysisbusinessEtoposidemedicine.drugAnnals of Oncology
researchProduct